Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye.~Exclusion Criteria:~* Pregnant or nursing women or women of child bearing potential without unless using an effective contraception~* Stroke or myocard infarction within 3 months prior to study~* History of malignancy within the past 5 years~* Uncontrolled hypertension~* Active infection or inflammation in any eye~* use of corticosteroids for at least 30 days in the last 6 months~* treatment with anti-angiogenic drugs in any eye within last 3 months~* Panretinal or focal/drid laser photocoagulation within the last few months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.5 mg (Type: EXPERIMENTAL): PRN Intravitreal injection
- Sham injection (Type: SHAM_COMPARATOR): As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).